Cell News and Research

RSS

‘Moving molecule’ therapy for severe spinal cord injury

In this interview, News-Medical speaks to Dr. Stupp about his recent research into a therapy involving dancing molecules for the treatment of severe spinal cord injury.

7 Dec 2021

Possible impact of spike protein mutations on SARS-CoV-2 Omicron variant

The current study not only analyses the mutations in the Omicron spike variant but classifies various combinations of spike mutations into groups.

7 Dec 2021

Exploring SARS-CoV-2 vaccine responsiveness in immunosuppressed patients

A new study indicates an immunological response to SARS-CoV-2 vaccines in immunosuppressed patients that were comparable to healthy patients.

7 Dec 2021

Impact of post-translational modifications in the pathogenicity of SARS-CoV-2

A new study provides understanding of the intricate roles and functions of the different elements of spike proteins and shows how the spike protein samples a crowded surface of its host cell via the glycans.

7 Dec 2021

Immune response of Pfizer vaccinees who received Moderna or Pfizer booster

A new preprint discusses the immune boost resulting from homologous or heterologous booster doses in individuals fully vaccinated with two doses of the Pfizer vaccine.

7 Dec 2021

Method for inactivation and direct RT-qPCR of SARS-CoV-2

Researchers from the University of Edinburgh have been exploring ways to optimize this process further, allowing RT-qPCR to work more efficiently by eliminating one of the key steps.

7 Dec 2021

Metrion Biosciences expands ion channel drug discovery service capabilities and in-house expertise

Metrion today announced it has expanded its capabilities and expertise through the addition of automated low volume liquid handling capability.

From Metrion Biosciences Limited 7 Dec 2021

Study suggests algal polysaccharide may be a promising anti-COVID-19 candidate

Researchers from the Rensselaer Polytechnic Institute have been investigating the potential of rhamnan sulfate as an antiviral agent.

7 Dec 2021

Scientists develop and characterize variant-specific vaccines against SARS-CoV-2

In a recent study conducted at Yale University, USA, scientists have investigated the immunogenicity of mRNA-based coronavirus disease 2019 (COVID-19) vaccine candidates encoding the spike proteins of different severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants. The findings reveal that the vaccines induce robust immune responses against SARS-CoV-2 variants. The study is currently available on the bioRxiv* preprint server.

6 Dec 2021

COVID-19 severity is correlated with T cell receptor repertoire signatures

In a new study published in the bioRxiv* preprint server, researchers found that specific TCR sequences predicted the severity of coronavirus disease 2019 (COVID-19) infection. Additionally, there was evidence of increased CDR3 sequences and changes in k-mer motifs for patients with severe illness.

6 Dec 2021

Simple quantitative framework to understand the pathogenesis of severe COVID-19

Researchers from Los Alamos National Laboratory in the United States developed a model to explain why severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections induce high inflammatory levels.

6 Dec 2021

SARS-CoV-2 S2 immunization as a pan-coronavirus vaccine approach

A new mouse model suggests that prior HCoV-OC43 S immunity primes neutralising antibody responses to otherwise subimmunogenic SARS-CoV-2 S exposure as well as promotes S2-targeting antibody responses.

6 Dec 2021

Scientists find infection of sustentacular cells in the olfactory epithelium of COVID-19 patients

It is now widely known that COVID-19 is associated with the transient or long-term loss of olfaction (the sense of smell) but the mechanisms remain obscure.

6 Dec 2021

Novel monoclonal antibody could help revolutionize treatment of children with high-risk neuroblastoma

Survival rates increased about 20% for children with high-risk neuroblastoma enrolled in a St. Jude Children’s Research Hospital clinical trial that included a novel monoclonal antibody produced onsite. The findings appeared today in the Journal of Clinical Oncology.

6 Dec 2021